Results 71 to 80 of about 101,617 (297)

Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment [PDF]

, 2016
Dipeptidyl peptidase-4 (DPP-4) inhibitors are widely used in the management of patients with type 2 diabetes mellitus (T2DM) and renal impairment (RI). A systematic literature review was performed to compare the efficacy and safety of DPP-4 inhibitors in
Per-Henrik Groop, Thomas, Merlin C., Merlin C. Thomas, Groop, PH, Ong, Siew Hwa, Groop, Per-Henrik, Siew Hwa Ong, Ayyagari, Rajeev, Paldánius, PM, Ong, SH, Thomas, MC, Paldanius, Paivi M., Rajeev Ayyagari, Ayyagari, R, Päivi M. Paldánius   +14 more
core   +1 more source

Renoprotective Effect of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus

Frontiers in Pharmacology, 2017
Diabetic nephropathy is one of three major complications of diabetes mellitus, often leading to chronic renal failure requiring dialysis. Recently developed dipeptidyl peptidase-4 (DPP-4) inhibitors may exhibit renoprotective effects in addition to ...
Hiroki Esaki, Hiroki Esaki, Tomoya Tachi, Tomoya Tachi, Chitoshi Goto, Ikuto Sugita, Yuta Kanematsu, Aki Yoshida, Kosuke Saito, Yoshihiro Noguchi, Yuki Ohno, Satoshi Aoyama, Masahiro Yasuda, Takashi Mizui, Masumi Yamamura, Hitomi Teramachi, Hitomi Teramachi   +16 more
doaj   +1 more source

Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus

BMC Pharmacology and Toxicology, 2020
Background The purpose of this study was to evaluate and compare the effects on laboratory parameters among monotherapy with five DPP-4 inhibitors in patients with type 2 diabetes mellitus (DM). Methods We identified cohorts of new sitagliptin users (n = 
Yayoi Nishida, Yasuo Takahashi, Kotoe Tezuka, Hayato Akimoto, Tomohiro Nakayama, Satoshi Asai   +5 more
doaj   +1 more source

Role of DPP-4 inhibitors in the management of type 2 diabetes [PDF]

, 2018
Among various insulinotropic agents used in treatment of Type 2 DM, inclusion of DPP4 inhibitors are considered as major breakthrough as far as new drug development is concerned.
., Ramesh, Gupta, D. D.
core   +2 more sources

A genetic variant in GLP1R is associated with response to DPP-4 inhibitors in patients with type 2 diabetes [PDF]

, 2017
Incretin hormone-based therapy in type 2 diabetes has been widely used, and dipepdityl peptidase-4 (DPP-4) inhibitors, which prevent incretin degradation, have become popular oral hypoglycemic agents.
박혜선, 이용호, 이상학, 한유진, 강은석, 왕혜진, 김철훈   +6 more
core   +1 more source

Effect of switching to teneligliptin from other dipeptidyl peptidase‐4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease

Journal of Diabetes Investigation, 2019
Aims/Introduction The objective of the present study was to elucidate the effect of switching to teneligliptin from other dipeptidyl peptidase‐4 (DPP‐4) inhibitors on glucose control and renoprotection in type 2 diabetes mellitus patients with diabetic ...
Munehiro Kitada, Yoshio Ogura, Kyoko Nitta, Mizue Fujii, Keizo Kanasaki, Kazunori Konishi, Yasuo Iida, Atsushi Nakagawa, Daisuke Koya   +8 more
doaj   +1 more source

Alogliptin – the new member of DPP-4 inhibitors class [PDF]

, 2014
This review presents data on the efficacy and safety of alogliptin, a new representative of the DPP-4 inhibitors, in adult patients with type2 diabetes mellitus (DM type 2) as monotherapy or in combination with metformin, pioglitazone, glibenclamide and ...
Nina Aleksandrovna Petunina, Anna Leont'evna Terekhova   +1 more
core   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Design, Synthesis, and Pharmacological Evaluation of Fused β‑Homophenylalanine Derivatives as Potent DPP‑4 Inhibitors [PDF]

, 2015
Dipeptidyl peptidase-4 (DPP-4) inhibitors are accepted as a favorable class of agents for the treatment of type 2 diabetes. Herein, a series of fused β-homophenylalanine derivatives as novel DPP-4 inhibitors were designed, synthesized, and evaluated for ...
Zhen Wang (72451), Hualiang Jiang (19452), Tao Jiang (28401), Yuren Zhou (420654), Weiliang Zhu (19448), Qiang Zhang (45005), Qiang Shao (112168), Bo Li (112195), Xiangrui Jiang (1601968), Kaixian Chen (19449), Jingshan Shen (1601962), Peng Sun (112156), Heyao Wang (420655), Jianming Zhu (1393405), Zhuxi Chen (1601965)   +14 more
core   +1 more source